Trending: AstraZeneca Reaches Treg Cell Therapies Agreement With Quell Therapeutics
09 Juni 2023 - 12:04PM
Dow Jones News
0934 GMT - AstraZeneca is among the most mentioned companies
across news items over the past four hours, according to Factiva
data, after the pharmaceutical company said it had reached an
agreement with Quell Therapeutics to develop, manufacture and
commercialize engineered T-regulatory, or Treg, cell therapies for
autoimmune diseases. Under the agreement, Quell will receive $85
million upfront in the form of a cash payment and an equity
investment. The Anglo-Swedish company said that if successful,
Quell is eligible to receive more than $2 billion for further
development and commercialization milestones plus tiered royalties.
The pharma giant said the deal--which encompasses a collaboration,
an exclusive option and license agreement--is focused on type 1
diabetes and inflammatory bowel disease. "This is aligned with our
strategy to target underlying disease drivers to stop or slow
disease progression and ultimately accelerate the delivery of
transformative care to patients with chronic autoimmune
conditions," AstraZeneca said. Dow Jones & Co. owns Factiva.
(anthony.orunagoriainoff@dowjones.com)
(END) Dow Jones Newswires
June 09, 2023 05:49 ET (09:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024